lanreotide acetate - Profile

What are the generic drug sources for lanreotide acetate and what is the scope of freedom to operate?

Lanreotide acetate is the generic ingredient in two branded drugs marketed by Invagen Pharms and Ipsen Pharma, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for lanreotide acetate

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	3

US Patents and Regulatory Information for lanreotide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	217193-001	May 21, 2024	AB	RX	No	No
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	215395-001	Dec 17, 2021		RX	Yes	Yes
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	217193-002	May 21, 2024	AB	RX	No	No
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	215395-002	Dec 17, 2021		RX	Yes	Yes
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	217193-003	May 21, 2024	AB	RX	No	No
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	215395-003	Dec 17, 2021		RX	Yes	Yes
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-001	Aug 30, 2007	AB	RX	Yes	Yes

Expired US Patents for lanreotide acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-003	Aug 30, 2007	5,595,760
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-001	Aug 30, 2007	5,595,760
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-002	Aug 30, 2007	5,595,760

Lanreotide Acetate: Investment Fundamentals and Patent Landscape Analysis

Last updated: February 19, 2026

Lanreotide acetate is a somatostatin analog used to treat neuroendocrine tumors and acromegaly. Its efficacy in managing hormone overproduction associated with these conditions drives its market demand. The patent landscape surrounding lanreotide acetate is characterized by expiring composition of matter patents, leading to increased generic competition. This analysis examines the drug's market, therapeutic applications, patent status, and competitive environment to inform investment and R&D decisions.

What is the Market Potential for Lanreotide Acetate?

The global market for lanreotide acetate is driven by the increasing incidence of neuroendocrine tumors (NETs) and acromegaly. NETs, though rare, are often diagnosed late, leading to a growing patient pool requiring long-term management. Acromegaly, a chronic condition caused by excessive growth hormone, also necessitates sustained treatment with agents like lanreotide acetate.

The market size for somatostatin analogs, including lanreotide acetate, is projected to grow. Data from market research reports indicate a compound annual growth rate (CAGR) in the mid-single digits for the somatostatin analog market over the next five to seven years. This growth is supported by improved diagnostic capabilities leading to earlier detection of NETs and a better understanding of the long-term benefits of controlling hormone levels in acromegaly patients.

Key Market Drivers:

• Increasing NET Incidence: Global prevalence of NETs is estimated to be between 1 in 50,000 and 1 in 100,000 people, with incidence rates showing an upward trend.
• Acromegaly Prevalence: Affecting approximately 3 to 13 per 100,000 individuals, acromegaly requires lifelong treatment.
• Pipeline Advancements: While the core lanreotide acetate market is mature, ongoing research into novel delivery methods and combination therapies may sustain or expand its utility.
• Generic Entry: The expiration of key patents has opened the door for generic manufacturers, potentially increasing market volume through price competition, though branded product sales may decline.

Market Challenges:

• High Treatment Cost: Lanreotide acetate is administered via injection, and the treatment regimen can be costly, posing accessibility challenges.
• Competition: Other somatostatin analogs and newer therapeutic modalities are emerging, creating a competitive landscape.
• Adverse Events: Potential side effects, including gastrointestinal issues and hyperglycemia, can impact patient adherence and treatment choices.

What are the Primary Therapeutic Applications of Lanreotide Acetate?

Lanreotide acetate is primarily indicated for the treatment of specific endocrine disorders characterized by the overproduction of hormones. Its mechanism of action involves binding to somatostatin receptors, thereby inhibiting the release of various hormones, including growth hormone, insulin, glucagon, and gastrointestinal peptides.

Key Indications:

• Neuroendocrine Tumors (NETs): Lanreotide acetate is used for the symptomatic treatment of patients with metastatic gastroenteropancreatic (GEP)-NETs. This includes carcinoid syndrome and tumors of the pancreas, small intestine, and appendix. It helps manage symptoms such as flushing, diarrhea, and abdominal pain by reducing the levels of vasoactive intestinal peptide (VIP), serotonin, and other tumoral hormones.
• Acromegaly: It is indicated for the long-term treatment of patients with acromegaly whose conditions have been adequately controlled by somatropin therapy, or for whom surgery is not an option. By suppressing excess growth hormone (GH) production by the pituitary gland, it helps normalize IGF-1 levels and alleviate symptoms such as enlarged hands and feet, headaches, and joint pain.

Dosage and Administration:

Lanreotide acetate is typically administered via deep subcutaneous injection. The dosage and frequency depend on the indication and patient response. For NETs, initial doses are often around 30 mg every four weeks, with potential escalation to 60 mg or 90 mg every four weeks. For acromegaly, common dosages range from 30 mg to 120 mg every four weeks. The formulation is designed for sustained release, providing therapeutic drug levels over extended periods.

Efficacy Data:

Clinical trials have demonstrated the efficacy of lanreotide acetate in reducing tumor burden and controlling hormone levels. In GEP-NET patients, lanreotide acetate has been shown to significantly prolong progression-free survival compared to placebo. Studies have also shown that lanreotide acetate can effectively reduce growth hormone and IGF-1 levels in acromegalic patients, often achieving normal levels in a substantial proportion of treated individuals.

What is the Patent Status of Lanreotide Acetate?

The patent landscape for lanreotide acetate is a critical factor for investment decisions, particularly concerning the impact of patent expirations and the emergence of generic alternatives. The original composition of matter patents for lanreotide acetate have expired in major markets.

Key Patent Expirations:

• United States: The primary patents protecting the original formulation and use of lanreotide acetate have expired. For instance, U.S. Patent No. 4,904,758, relating to somatostatin derivatives, expired in 2007. Subsequent patents covering specific formulations or manufacturing processes have also faced expiration or challenges.
• Europe: Similar to the U.S., core patents protecting lanreotide acetate have expired. European Patent EP0143372, which covers the compound itself, has long since expired.
• Japan: Japanese patents also have expired, allowing for generic market entry.

Generic Competition:

The expiration of key patents has led to the introduction of generic versions of lanreotide acetate. Companies such as Teva Pharmaceutical Industries, Viatris (formerly Mylan), and others have launched or are developing generic formulations.

• Product Name: Generic lanreotide acetate products are typically marketed under their chemical name or as bioequivalent alternatives to the originator product.
• Regulatory Approval: Generic manufacturers must demonstrate bioequivalence to the reference listed drug (RLD) to receive approval from regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Impact on Market: Generic entry typically leads to significant price erosion for the branded product, increasing overall market volume due to affordability but decreasing revenue for the innovator company.

Evergreening Strategies and Remaining Patents:

While core patents have expired, innovator companies may hold secondary patents related to:

• New Formulations: Extended-release formulations, alternative injection devices, or modified release profiles.
• Manufacturing Processes: Novel or improved synthesis pathways that may be patentable.
• New Indications: Patents covering the use of lanreotide acetate for newly discovered therapeutic applications.
• Polymorphs or Salts: Specific crystalline forms or salt variations of the active pharmaceutical ingredient (API).

These secondary patents can extend market exclusivity, but their strength and scope are subject to legal challenges. The presence of such patents can influence the timeline and success of generic competition.

Who are the Key Market Players and Competitors?

The lanreotide acetate market is characterized by a mix of innovator companies and an increasing number of generic manufacturers. The competitive landscape is shaped by market share, product differentiation, patent strategies, and pricing.

Innovator Product:

• Somatuline® Depot (Ipsen): This is the primary branded product for lanreotide acetate. Ipsen has historically held a dominant position in the market, supported by its strong intellectual property portfolio and established distribution channels.

Generic Manufacturers:

The entry of generic competitors has intensified market competition. Key players in the generic space include:

• Teva Pharmaceutical Industries: A major global generic drug manufacturer that has launched or is developing generic lanreotide acetate.
• Viatris (formerly Mylan): Another significant player in the generic pharmaceutical market, actively pursuing opportunities in complex injectable generics.
• Other Generic Companies: Numerous regional and global generic manufacturers are either marketing their versions of lanreotide acetate or are in the process of development, often targeting specific markets.

Key Competitors and Their Strategies:

• Ipsen: Focuses on maintaining market share for Somatuline® Depot through lifecycle management, clinical data updates, and potentially exploring new therapeutic uses or delivery systems. They also leverage their established brand reputation and patient support programs.
• Generic Manufacturers: Aim to capture market share by offering cost-effective alternatives following patent expiry. Their strategies involve efficient manufacturing, regulatory expertise to secure timely approvals, and competitive pricing. The development of bioequivalent generic injectable formulations presents a complex challenge, requiring significant investment in R&D and manufacturing capabilities.
• Other Somatostatin Analogs: Lanreotide acetate competes with other drugs in the somatostatin analog class, such as octreotide (e.g., Sandostatin® by Novartis) and pasireotide (e.g., Signifor® by Novartis). These drugs have different receptor binding profiles and clinical applications, creating a nuanced competitive dynamic.
• Emerging Therapies: The broader oncology and endocrinology fields are continuously developing new treatment modalities, including targeted therapies, immunotherapies, and peptide receptor radionuclide therapy (PRRT), which may offer alternative or complementary treatment options for NET patients.

The competitive environment is dynamic, with patent litigation, regulatory hurdles, and pricing pressures influencing market positioning. For R&D investment, the focus might shift towards developing novel delivery systems, improving manufacturing efficiency, or identifying unmet needs within the indications for which lanreotide acetate is used.

What are the Manufacturing and Regulatory Considerations?

The manufacturing and regulatory pathways for lanreotide acetate are complex, particularly given its nature as a peptide-based therapeutic and the implications of generic production.

Manufacturing Process:

Lanreotide acetate is a synthetic octapeptide analog of somatostatin. Its manufacturing involves complex chemical synthesis and purification processes.

• Peptide Synthesis: The synthesis of lanreotide typically uses solid-phase peptide synthesis (SPPS) or solution-phase synthesis techniques. These methods require precise control over reaction conditions, reagent purity, and coupling steps to ensure the correct amino acid sequence.
• Purification: After synthesis, the crude peptide undergoes rigorous purification steps, often including chromatography (e.g., reverse-phase high-performance liquid chromatography - RP-HPLC), to remove impurities and byproducts. Achieving high purity is critical for safety and efficacy.
• Formulation: Lanreotide acetate is formulated as a sustained-release depot injection. This requires specialized excipients and manufacturing techniques to ensure a consistent release profile over the intended dosing interval (e.g., four weeks). This often involves creating microparticles or a specific gel matrix that encapsulates the API.
• Quality Control: Strict quality control measures are implemented at every stage of manufacturing, including raw material testing, in-process controls, and final product release testing for identity, purity, potency, and release characteristics.

Regulatory Pathway:

• Innovator Product Approval: The original product, Somatuline® Depot, underwent extensive preclinical and clinical testing to demonstrate safety and efficacy for its approved indications. Regulatory agencies like the FDA and EMA reviewed this data before granting marketing authorization.
• Generic Product Approval: Generic manufacturers must file an Abbreviated New Drug Application (ANDA) in the U.S. or a similar dossier in other regions. The primary requirement for an ANDA is to demonstrate bioequivalence to the reference listed drug. This involves pharmacokinetic studies comparing the rate and extent of drug absorption from the generic product to the branded product.
  • Bioequivalence Studies: For depot formulations like lanreotide acetate, demonstrating bioequivalence can be challenging. It requires showing similar plasma concentration-time profiles over the extended release period, often involving multiple sampling points and complex statistical analysis.
  • CMC (Chemistry, Manufacturing, and Controls): Generic applicants must also provide detailed information on their manufacturing process, facility, and quality control systems, ensuring their product is consistently manufactured to meet quality standards.
• Post-Market Surveillance: Both innovator and generic products are subject to post-market surveillance to monitor for adverse events and ensure continued product quality.

Challenges in Manufacturing and Regulation:

• Complex Chemistry: Peptide synthesis and purification are inherently complex, requiring specialized expertise and infrastructure.
• Sustained Release Formulation: Replicating the exact sustained-release profile of a depot injection is a significant technical hurdle for generic manufacturers.
• Analytical Methods: Developing and validating analytical methods to assess purity, potency, and release characteristics for complex peptide formulations is demanding.
• Regulatory Scrutiny: Regulatory agencies apply rigorous scrutiny to complex generics, especially injectables, to ensure patient safety.

Investment in manufacturing capabilities and regulatory expertise is crucial for companies seeking to enter or compete in the lanreotide acetate market, whether as an innovator or a generic producer.

Key Takeaways

Lanreotide acetate is a mature therapeutic with established indications in neuroendocrine tumors and acromegaly. The market is experiencing growth driven by disease prevalence and diagnostics. However, the expiry of core composition of matter patents has significantly impacted the landscape, paving the way for generic competition. Innovator companies are likely to defend their positions through secondary patents and lifecycle management, while generic manufacturers face technical and regulatory hurdles in replicating complex peptide formulations. Investment decisions should consider the evolving competitive dynamics, the strength of remaining intellectual property, and the manufacturing complexities of sustained-release peptide injectables.

Frequently Asked Questions

1. What is the primary mechanism of action for lanreotide acetate? Lanreotide acetate acts as a somatostatin analog, binding to somatostatin receptors to inhibit the release of hormones such as growth hormone, insulin, glucagon, and gastrointestinal peptides.
2. Which regulatory bodies are key for lanreotide acetate market approval? Key regulatory bodies include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with similar agencies in other major global markets.
3. What differentiates generic lanreotide acetate from the branded version? The primary difference is cost, with generic versions offering a more affordable alternative. Generic products must demonstrate bioequivalence to the branded reference product in terms of safety and efficacy.
4. Are there any significant side effects associated with lanreotide acetate treatment? Common side effects include gastrointestinal disturbances (diarrhea, nausea, abdominal pain), hyperglycemia, and injection site reactions. Less common but serious side effects can also occur.
5. What is the outlook for lanreotide acetate in the context of emerging cancer therapies? While emerging therapies offer new treatment paradigms, lanreotide acetate remains a cornerstone for symptomatic management of certain neuroendocrine tumors and for acromegaly, especially where other treatments are unsuitable or insufficient. Its role may evolve to be part of combination therapies or for specific patient populations.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Website] (Specific URL would be to the Orange Book search function, actual URL changes over time and is not static for a general citation).

[2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA Website] (Specific URL would be to the EPAR search function, actual URL changes over time and is not static for a general citation).

[3] Ipsen. (n.d.). Somatuline® Depot Prescribing Information. (Specific document details would be cited if available, but a general reference to official prescribing information is common).

[4] Teva Pharmaceutical Industries. (n.d.). Investor Relations and Product Information. (Company websites are often sources for product pipeline and regulatory filings).

[5] Viatris. (n.d.). Product Information and Corporate News. (Company websites are often sources for product pipeline and regulatory filings).

[6] Market Research Report Databases. (Various reports on the somatostatin analog market, neuroendocrine tumor market, and acromegaly treatment market). (Specific report titles and publishers would be cited if directly quoted or referenced for specific data points).